Martine P. Roudier

University of Washington — United States

Medicine · Health Sciences

37h-index5.6kcitations192works8.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(88), Radiopharmaceutical Chemistry and Applications(31), Bone health and treatments(29), Melanoma and MAPK Pathways(28), PI3K/AKT/mTOR signaling in cancer(24)

Publications192 total

Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer
Journal of Clinical Investigation·2025· 8 citedOpen Access
Abstract 1438: HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity
Cancer Research·2025
Abstract PR011: Advance prostate cancer detection through epigenomic profiling of cell-free DNA
Clinical Cancer Research·2024
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies
Proceedings of the National Academy of Sciences·2024· 40 citedOpen Access
Molecular Pathology of Prostate Cancer
Clinics in Laboratory Medicine·2024· 11 cited
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
npj Precision Oncology·2024· 26 citedOpen Access
MP65-02 AIM HIGH: EPIGENETIC MODULATION AND IMMUNE STIMULATION IN BLADDER CANCER
The Journal of Urology·2024
Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies
2024· 6 citedOpen Access
AIM HIGH: EPIGENETIC MODULATION AND IMMUNE STIMULATION IN BLADDER CANCER
Urologic Oncology Seminars and Original Investigations·2024
AIM high: Epigenetic modulation and immune stimulation in bladder cancer.
Journal of Clinical Oncology·2024· 1 cited
Abstract A094: LIN28B/HMGA2 axis accelerates PDA by promoting oncogenic protein synthesis
Cancer Research·2024
Assessment of Cell Surface Targets in Metastatic Prostate Cancer: Expression Landscape and Molecular Correlates
2023· 4 citedOpen Access
Characterization of <scp>HOXB13</scp> expression patterns in localized and metastatic castration‐resistant prostate cancer
The Journal of Pathology·2023· 24 citedOpen Access
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models
Journal of Clinical Investigation·2023· 24 citedOpen Access
Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth
Oncogene·2023· 6 citedOpen Access
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study
Clinical Genitourinary Cancer·2023· 30 citedOpen Access
Abstract LB298: Molecular phenotype classification of metastatic prostate cancer by cell-free DNA methylation analysis
Cancer Research·2023
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
Nature Communications·2023· 110 citedOpen Access
Supplementary Figures 1-19, Tables 1-2 from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
2023Open Access
Supplementary Figures 1-19, Tables 1-2 from Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Lawrence D. True(23), Peter S. Nelson(18), Colm Morrissey(18), Robert L. Vessella(15), Eva Corey(15), Ilsa M. Coleman(14), Celestia S. Higano(12), Michael C. Haffner(8), Paul H. Lange(8), Lisha G. Brown(6), Hung‐Ming Lam(6), Roman Gulati(6), William C. Dougall(6), Bruce Montgomery(6), Xiaotun Zhang(5), Ruth F. Dumpit(5), Radhika A. Patel(5), John K. Lee(5), Erolcan Sayar(5), Gemma N. Jones(4)